WO2007138472A3 - Dérivés de la triazolopyridazine - Google Patents

Dérivés de la triazolopyridazine Download PDF

Info

Publication number
WO2007138472A3
WO2007138472A3 PCT/IB2007/001446 IB2007001446W WO2007138472A3 WO 2007138472 A3 WO2007138472 A3 WO 2007138472A3 IB 2007001446 W IB2007001446 W IB 2007001446W WO 2007138472 A3 WO2007138472 A3 WO 2007138472A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
formula
triazolopyridazine derivatives
relates
triazolopyridazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/001446
Other languages
English (en)
Other versions
WO2007138472A2 (fr
Inventor
Hengmiao Cheng
Jingrong Jean Cui
Jacqui Elizabeth Hoffman
Lei Jia
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to CA002651979A priority Critical patent/CA2651979A1/fr
Priority to EP07734734A priority patent/EP2032578A2/fr
Priority to JP2009512702A priority patent/JP2009538899A/ja
Publication of WO2007138472A2 publication Critical patent/WO2007138472A2/fr
Publication of WO2007138472A3 publication Critical patent/WO2007138472A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (I) ou un de leurs sels pharmaceutiquement acceptable, dans laquelle R1, R2, R3 et R3' sont tels que définis ici. L'invention concerne également des compositions pharmaceutiques contenant les composés de formule (I) et des procédés de traitement des affections hyperprolifératives chez un mammifère par l'administration des composés de formule (I).
PCT/IB2007/001446 2006-05-30 2007-05-18 Dérivés de la triazolopyridazine Ceased WO2007138472A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002651979A CA2651979A1 (fr) 2006-05-30 2007-05-18 Derives de la triazolopyridazine
EP07734734A EP2032578A2 (fr) 2006-05-30 2007-05-18 Dérivés de la triazolopyridazine
JP2009512702A JP2009538899A (ja) 2006-05-30 2007-05-18 トリアゾロピリダジン誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80346906P 2006-05-30 2006-05-30
US60/803,469 2006-05-30

Publications (2)

Publication Number Publication Date
WO2007138472A2 WO2007138472A2 (fr) 2007-12-06
WO2007138472A3 true WO2007138472A3 (fr) 2008-02-07

Family

ID=38626862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/001446 Ceased WO2007138472A2 (fr) 2006-05-30 2007-05-18 Dérivés de la triazolopyridazine

Country Status (4)

Country Link
EP (1) EP2032578A2 (fr)
JP (1) JP2009538899A (fr)
CA (1) CA2651979A1 (fr)
WO (1) WO2007138472A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987250B2 (en) 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds
US9006229B2 (en) 2011-04-21 2015-04-14 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
US9102614B2 (en) 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9321777B2 (en) 2007-08-09 2016-04-26 Sanofi 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170103T1 (hr) 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR101083177B1 (ko) * 2006-10-23 2011-11-11 에스지엑스 파마슈티컬스, 인코포레이티드 트리아졸로-피리다진 단백질 키나제 조정제
WO2009005675A1 (fr) 2007-06-28 2009-01-08 Abbott Laboratories Nouvelles triazolopyridazines
FR2919870B1 (fr) * 2007-08-09 2014-05-16 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
UY31676A1 (es) 2008-02-28 2009-09-30 "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
US8394823B2 (en) 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
JP5596047B2 (ja) * 2008-11-19 2014-09-24 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
MX2011008452A (es) 2009-02-10 2011-12-16 Astrazeneca Ab Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
CA2762479A1 (fr) 2009-05-28 2010-12-02 Vertex Pharmaceuticals Incorporated Inhibiteurs de la proteine kinase c-met
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
CA2771432A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composes d'oximes heterocycliques
EA030141B1 (ru) * 2009-12-31 2018-06-29 Хатчисон Медифарма Лимитед Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EP2569315A1 (fr) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP2588455B1 (fr) * 2010-07-02 2018-04-04 Gilead Sciences, Inc. Dérivés de l'acide 2-quinolinyl-acétique en tant que composés antiviraux hiv
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
CA2848809A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituees en position 6 a activite tyrosine kinase
CN104447867B (zh) * 2013-09-17 2017-12-26 江苏天士力帝益药业有限公司 一种噻吩并哌啶衍生物、制备方法及其应用
WO2015134854A2 (fr) * 2014-03-06 2015-09-11 Oyagen, Inc. Antagonistes à petites molécules obtenus par dimérisation de vif à titre d'agents anti-vih et pouvant être utilisés à titre d'agents thérapeutiques
PL224660B1 (pl) * 2014-07-23 2017-01-31 Inst Immunologii I Terapii Doświadczalnej Nowe analogi 1,2,4-triazoli i sposób otrzymywania analogów 1,2,4-triazoli
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
CN106924260B (zh) * 2015-12-31 2018-05-25 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
MX2022009507A (es) * 2020-02-06 2022-11-09 London Pharmaceuticals And Res Corporation Ésteres de sulfato de cannabinoides, sus sales y usos de los mismos.
CN116969955B (zh) * 2023-09-25 2023-12-19 中国药科大学 一种[1,2,4]三唑[4,3-b]哒嗪类化合物及其制法与应用
WO2025098425A1 (fr) * 2023-11-09 2025-05-15 浙江华海药业股份有限公司 Procédé de préparation de modulateur du récepteur de la chimiokine et utilisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012236A1 (fr) * 2000-08-04 2002-02-14 Bayer Cropscience Ag Triazolopyrid(az)ines substituees en tant qu'agents de traitement des vegetaux (herbicides)
WO2004058769A2 (fr) * 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs des proteine kinases
EP1481977A1 (fr) * 2002-03-01 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. Compose heterocyclique azote
WO2007064797A2 (fr) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
WO2007075567A1 (fr) * 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines en tant que modulateurs de la tyrosine kinase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012236A1 (fr) * 2000-08-04 2002-02-14 Bayer Cropscience Ag Triazolopyrid(az)ines substituees en tant qu'agents de traitement des vegetaux (herbicides)
EP1481977A1 (fr) * 2002-03-01 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. Compose heterocyclique azote
WO2004058769A2 (fr) * 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs des proteine kinases
WO2007064797A2 (fr) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
WO2007075567A1 (fr) * 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines en tant que modulateurs de la tyrosine kinase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CUCEK, KARMEN ET AL: "Synthesis of novel [1,2,4]triazolo[4,3-b]pyridazines", ARKIVOC (GAINESVILLE, FL, UNITED STATES) [ONLINE COMPUTER FILE] , (5), 79-86 CODEN: AGFUAR URL: HTTP://WWW.ARKAT-USA.ORG/ARK/JOURNAL/VOLUME2/PART3/TISLER/MT-161/MT- 161.PDF, 2001, XP002459200 *
KOSARY ET AL.: "Preparation of New[1,2,4]Triazolo[4,3-b]pyridazines", PHARMAZIE, vol. 38, no. 6, 1983, pages 369 - 371, XP001536587 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321777B2 (en) 2007-08-09 2016-04-26 Sanofi 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors
US9102614B2 (en) 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
US9006229B2 (en) 2011-04-21 2015-04-14 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US8987250B2 (en) 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds
US9096586B2 (en) 2012-04-20 2015-08-04 Gilead Sciences, Inc. Therapeutic compounds

Also Published As

Publication number Publication date
WO2007138472A2 (fr) 2007-12-06
JP2009538899A (ja) 2009-11-12
CA2651979A1 (fr) 2007-12-06
EP2032578A2 (fr) 2009-03-11

Similar Documents

Publication Publication Date Title
WO2007138472A3 (fr) Dérivés de la triazolopyridazine
CA2510853A1 (fr) Derives de pyrrolopyrimidine
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
WO2007061360A3 (fr) Nouveau composes
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
WO2008012635A3 (fr) Dérivés d'amines utiles en tant qu'agents anticancéreux
TW200728307A (en) Novel spirochromanone derivatives
WO2007112000A3 (fr) Traitement de la douleur
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2005075425A3 (fr) Derives de bisaryluree
WO2007146856A3 (fr) Gamma lactames substitués utilisés en tant qu'agents thérapeutiques
WO2008006795A3 (fr) Composés d'indole
WO2005080352A3 (fr) Derives de quinazoline et leur utilisation therapeutique
WO2007020213A3 (fr) Derives de thiazolylpiperidines
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
WO2003074529A3 (fr) Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation
WO2006116148A3 (fr) Traitement de l'abus de substances toxiques
WO2006116733A3 (fr) Inhibiteurs des proteines kinases
WO2008008660A3 (fr) Composés thérapeutiques
TW200626158A (en) Naphthaline derivatives
WO2007046867A3 (fr) Derives de piperidine et leurs utilisations comme agents therapeutiques
WO2007131907A3 (fr) Dérivés de 1h-indol-5-yl-pipérazin-1-yl-méthanone
WO2007111983A3 (fr) Nouvelles combinaisons thérapeutiques pour le traitement ou la prévention de troubles psychotiques
TW200716547A (en) Piperidin-4-yl-amide derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07734734

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2651979

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009512702

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007734734

Country of ref document: EP